- Home
- LGCY vs LUCD Comparison
LGCY vs LUCD Comparison
Compare LGCY & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- LUCD
- Stock Information
- Founded
- LGCY 2009
- LUCD 2018
- Country
- LGCY United States
- LUCD United States
- Employees
- LGCY N/A
- LUCD N/A
- Industry
- LGCY
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LGCY
- LUCD Health Care
- Exchange
- LGCY NYSE
- LUCD Nasdaq
- Market Cap
- LGCY 117.7M
- LUCD 140.7M
- IPO Year
- LGCY 2024
- LUCD 2021
- Fundamental
- Price
- LGCY $11.05
- LUCD $1.26
- Analyst Decision
- LGCY Strong Buy
- LUCD Strong Buy
- Analyst Count
- LGCY 2
- LUCD 4
- Target Price
- LGCY $10.65
- LUCD $3.94
- AVG Volume (30 Days)
- LGCY 67.7K
- LUCD 1.2M
- Earning Date
- LGCY 05-15-2025
- LUCD 08-11-2025
- Dividend Yield
- LGCY N/A
- LUCD N/A
- EPS Growth
- LGCY 21.53
- LUCD N/A
- EPS
- LGCY 0.62
- LUCD N/A
- Revenue
- LGCY $58,970,210.00
- LUCD $4,173,000.00
- Revenue This Year
- LGCY $33.77
- LUCD $91.46
- Revenue Next Year
- LGCY $24.88
- LUCD $213.42
- P/E Ratio
- LGCY $17.67
- LUCD N/A
- Revenue Growth
- LGCY 37.92
- LUCD 39.89
- 52 Week Low
- LGCY $3.60
- LUCD $0.68
- 52 Week High
- LGCY $11.20
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- LUCD 46.57
- Support Level
- LGCY N/A
- LUCD $1.21
- Resistance Level
- LGCY N/A
- LUCD $1.34
- Average True Range (ATR)
- LGCY 0.00
- LUCD 0.08
- MACD
- LGCY 0.00
- LUCD -0.01
- Stochastic Oscillator
- LGCY 0.00
- LUCD 50.00
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.